Berkeley, CA
Synvivia is building genetically encoded biocontainment technologies that will enable the widespread use of synthetic biology outside of the laboratory. Synvivia has exclusive license to IP in all fields of use. Backed by Y Combinator, the National Institutes of Health, and industrial partnerships. Synvivia’s technology was developed at UC Berkeley with grants from the NSF and DARPA. The work was published in ACS Synthetic Biology and featured as an Editor’s Choice in Science Magazine.

Gabriel Lopez, Ph.D (CEO, Founder)

Stay Tuned

Subscribe to our newsletter and get updates on our portfolio companies.